Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC50=110 pM). Diprovocim stimulates the release of TNF-alpha from mouse macrophages (EC50=1.3 nM). Diprovocim activates downstream MAPK and NF-kappaB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses[1][2].